Success Stories
Highlights of the PCI news focused on Penn commercialization accomplishments
The Center for Breakthrough Medicines and Penn partner in the manufacturing of gene therapies
Penn’s Innovation in Process Science combines with CBM manufacturing capability to develop large-scale gene therapy manufacturing capacity, testing, and analytics
ŌNŌCOR launches ŌNŌ system
PCI startup ŌNŌCOR announced the first-in-human use of their ŌNŌ endovascular retrieval system for the removal of an intracardiac tumor.
Neuralert’s first product receives FDA Breakthrough Designation
Neuralert addresses the problem of late or undetected stroke in hospitalized patients.
Faculty Innovators are Celebrated
The 6th annual Celebration of Innovation returned in a hybrid format for 2021 with both attendees and award recipients participating in person and virtually.
Katalin Karikó, PhD, featured on the cover of Newsweek as one of America’s Greatest Disruptors
She was described as being one of the 50 visionaries whose career-long actions have had far-reaching impact.
Penn inventors named Heroes of the Year by Time Magazine
Drs. Katalin Kariko and Drew Weissman, inventors of the foundational RNA research that led to the COVID-19 vaccines, are two of researchers named by Time Magazine as their Heroes of the Year 2021.
Celebration of Innovation 2021 Recap and Recording
The event honors the patent recipients from the previous fiscal year, as well as, those partners, inventors, and startups that made exceptional achievements.
Penn Center for Innovation reports largest number of annual patents in 2021
The Penn Center for Innovation had the most-ever patents issued for Penn and its affiliates this year, according to the center's 2021 Year in Review.
Developing a chewing gum to reduce the incidence of Covid-19
A chewing gum impregnated with a plant-grown protein can serve as a “trap” for the SARS-CoV-2 virus, reducing viral load in the chewers saliva and potentially tamping down transmission.
A record-breaking year for innovation
With its highest number of patents issued, commercial agreements, corporate-sponsored research funding, and licensing revenue receipts in a single period, PCI experienced a landmark fiscal year.